IL13RA2 and neoplasm: In a study by Brown and colleagues (National Clinical Trial (NCT)02208362), multi-dose treatment with IL-13Rα2-CAR-T cells resulted in complete tumor regression for nearly eight months in a patient with disseminated glioblastoma [102].